IO Biotech (IOBT) Projected to Post Earnings on Wednesday

IO Biotech (NASDAQ:IOBT) will likely be posting its Q4 2025 results before the market opens on Wednesday, May 13th. Analysts expect IO Biotech to post earnings of ($0.10) per share for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, May 15, 2026 at 5:00 PM ET.

IO Biotech Price Performance

Shares of IOBT opened at $0.05 on Wednesday. IO Biotech has a 52 week low of $0.03 and a 52 week high of $2.79. The company has a quick ratio of 2.01, a current ratio of 2.01 and a debt-to-equity ratio of 18.29. The company has a market capitalization of $3.45 million, a price-to-earnings ratio of -0.04 and a beta of 0.88. The stock’s 50-day moving average price is $0.16 and its 200-day moving average price is $0.47.

Analysts Set New Price Targets

A number of equities analysts have issued reports on IOBT shares. Piper Sandler downgraded IO Biotech from an “overweight” rating to a “neutral” rating in a research report on Friday, January 23rd. Morgan Stanley downgraded IO Biotech from an “equal weight” rating to an “underweight” rating in a research report on Thursday, January 8th. Weiss Ratings reiterated a “sell (e+)” rating on shares of IO Biotech in a research report on Friday, March 27th. Finally, Wall Street Zen upgraded IO Biotech from a “sell” rating to a “hold” rating in a research report on Saturday, January 10th. Three equities research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Reduce” and an average price target of $3.50.

Hedge Funds Weigh In On IO Biotech

Hedge funds have recently bought and sold shares of the business. Jane Street Group LLC acquired a new position in shares of IO Biotech during the first quarter valued at approximately $26,000. NewEdge Advisors LLC purchased a new position in shares of IO Biotech in the second quarter valued at approximately $34,000. Marex Group plc purchased a new position in shares of IO Biotech in the second quarter valued at approximately $63,000. Boothbay Fund Management LLC purchased a new position in shares of IO Biotech in the third quarter valued at approximately $215,000. Finally, Millennium Management LLC purchased a new position in shares of IO Biotech in the third quarter valued at approximately $506,000. Hedge funds and other institutional investors own 54.76% of the company’s stock.

About IO Biotech

IO Biotech ApS is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, specializing in the development of novel immuno-oncology therapies. The company’s proprietary platform focuses on activating and sustaining anti-tumor immune responses by targeting the PD-L1 immune checkpoint. IO Biotech’s lead candidate, IO-VAC(R), is a peptide-based cancer vaccine designed to induce durable T-cell responses against PD-L1–expressing tumors.

Since its founding in 2013, IO Biotech has advanced IO-VAC(R) into multiple clinical trials, including Phase II studies in patients with metastatic melanoma.